Cardiac Dimensions, a Kirkland, Washington-, Sydney, Australia- and Frankfurt, Germany-based medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation, raised an additional $15.2m financing.
Backers included Life Sciences Partners, Aperture Venture Partners, Lumira Capital, M.H. Carnegie & Co., and Arboretum Ventures.
The company, which has raised $43m in total, intends to use the funds to conduct its REDUCE FMR clinical trial, a blinded, randomized clinical trial of a percutaneous mitral repair device in patients with functional mitral regurgitation (FMR) and to expand research and development projects and its commercial operations.
Led by Rick Stewart, Chief Executive Officer, Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company’s initial technology platform, the CARILLON Mitral Contour System, has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach.